Abstract
CD25, CD27, CD30 and CD40 are receptors for IL-2, CD70, CD153 and CD154, respectively, which provide important signaling for both B- and T-cell immune responses. We therefore examined the sera of patients with Waldenstrom’s macroglobulinemia (WM), a B-cell disorder characterized by excess IgM secreting bone marrow lymphoplasmacytic cells (LPC) for the presence of soluble CD25, CD27, CD30, CD40, IL-2, CD153, and CD154. Sera were from patients with active disease and off-therapy. Sera from healthy age matched donors (HD) was used for controls. The results of these studies were as follows:
. | . | WM ELISA Results . | HD ELISA Results . | ||||
---|---|---|---|---|---|---|---|
. | p-value . | n= . | median . | range . | n= . | median . | range . |
sCD25 pg/ml | 2.647x10−6 | 41 | 3418.99 | 3–19756.2 | 20 | 573.6 | 184.96–891.03 |
IL-2 pg/ml | 0.72385 | 41 | 22.96 | 3–76.83 | 20 | 11.07 | 5.64–64.7 |
sCD27 U/ml | 2.4727x10−7 | 26 | 7.45 | 0–19.42 | 10 | 0 | 0–2.78 |
sCD70 | ND | ND | ND | ND | ND | ND | ND |
sCD30 U/ml | 0.00088 | 25 | 89.25 | 0–550.81 | 15 | 39.12 | 0–135.25 |
sCD153 ng/ml | 0.68388 | 25 | 8.18 | 0–43.8 | 15 | 5.65 | 0–24.82 |
sCD40 pg/ml | 0.02484 | 25 | 101.39 | 11.76–584.99 | 11 | 50.73 | 0–150.5 |
sCD154 pg/ml | 0.81317 | 55 | 949.58 | 92–4973.16 | 17 | 1078.03 | 351.88–2323.38 |
. | . | WM ELISA Results . | HD ELISA Results . | ||||
---|---|---|---|---|---|---|---|
. | p-value . | n= . | median . | range . | n= . | median . | range . |
sCD25 pg/ml | 2.647x10−6 | 41 | 3418.99 | 3–19756.2 | 20 | 573.6 | 184.96–891.03 |
IL-2 pg/ml | 0.72385 | 41 | 22.96 | 3–76.83 | 20 | 11.07 | 5.64–64.7 |
sCD27 U/ml | 2.4727x10−7 | 26 | 7.45 | 0–19.42 | 10 | 0 | 0–2.78 |
sCD70 | ND | ND | ND | ND | ND | ND | ND |
sCD30 U/ml | 0.00088 | 25 | 89.25 | 0–550.81 | 15 | 39.12 | 0–135.25 |
sCD153 ng/ml | 0.68388 | 25 | 8.18 | 0–43.8 | 15 | 5.65 | 0–24.82 |
sCD40 pg/ml | 0.02484 | 25 | 101.39 | 11.76–584.99 | 11 | 50.73 | 0–150.5 |
sCD154 pg/ml | 0.81317 | 55 | 949.58 | 92–4973.16 | 17 | 1078.03 | 351.88–2323.38 |
Considering our recent studies demonstrating a role for mast cells (MC) in supporting WM cell growth (JCO 2004 22:571S), we examined bone marrow LPC along with MC from WM patients for expression of CD25, CD27 and CD40 and/or their ligands by flow cytometry and RT-PCR analysis. The results of these studies are as follows:
. | Flow Cytometry . | RT-PCR . | ||
---|---|---|---|---|
. | WM . | MC . | WM . | MC . |
CD25 | 4/10 (40%) | 2/7 (29%) | 7/9 (78%) | 7/15 (47%) |
IL-2 | ND | ND | ND | ND |
CD27 | 5/12 (42%) | 2/8 (25%) | 7/7 (100%) | 4/7 (57%) |
CD70 | 6/6 (100%) | 10/11 (91%) | 7/7 (100%) | 2/7 (29%) |
CD30 | 1/21 (4.7%) | ND | ND | ND |
CD153 | 3/7 (43%) | 12/13 (92%) | 2/2 (100%) | 9/11 (82%) |
CD40 | 25/30 (83%) | ND | ND | ND |
CD154 | 2/3 (67%) | 9/13 (69%) | 7/9 (78%) | ND |
. | Flow Cytometry . | RT-PCR . | ||
---|---|---|---|---|
. | WM . | MC . | WM . | MC . |
CD25 | 4/10 (40%) | 2/7 (29%) | 7/9 (78%) | 7/15 (47%) |
IL-2 | ND | ND | ND | ND |
CD27 | 5/12 (42%) | 2/8 (25%) | 7/7 (100%) | 4/7 (57%) |
CD70 | 6/6 (100%) | 10/11 (91%) | 7/7 (100%) | 2/7 (29%) |
CD30 | 1/21 (4.7%) | ND | ND | ND |
CD153 | 3/7 (43%) | 12/13 (92%) | 2/2 (100%) | 9/11 (82%) |
CD40 | 25/30 (83%) | ND | ND | ND |
CD154 | 2/3 (67%) | 9/13 (69%) | 7/9 (78%) | ND |
The above studies demonstrate high levels of circulating immunoregulatory receptors, and expression of these receptors and/or their ligands on WM tumor and mast cells. Studies addressing their role in immune dysregulation in WM are underway.
Author notes
Corresponding author
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal